European Commission approves Pfizer's RSV vaccine for adults at increased risk of disease

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

European Commission approves Pfizer's RSV vaccine for adults at increased risk of disease

, Reuters - 3:00 AM ET 4/1/2025 default

April 1 (Reuters) - The European Commission approved Pfizer's ( PFE ) respiratory syncytial virus (RSV) vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease, the company said on Tuesday.

The expanded EU approval is for Pfizer's ( PFE ) Abrysvo vaccine, which was backed by the European Medicines Agency's panel of experts in March.

It is a blow for rival drugmaker GSK which has not yet won approval for this population for its RSV vaccine. (Reporting by Maggie Fick in London; Editing by Savio D'Souza)

(c) Reuters 2025. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.